Aclaris Therapeutics ACRS EBITDA margin

EBITDA margin at other companies

IncyteINCY

32.2%+4.5pp

Upstream Bio, Inc.UPB

-5,376.3%+1,392pp

Avalo TherapeuticsAVTX

-15,497.7%-17,225pp

Shattuck Labs, Inc.STTK

-5,222.2%-14,609pp

AnaptysBio, Inc.ANAB

17.8%+9.7pp

Alumis Inc.ALMS

-5,322.1%—

FAQ

What is Aclaris Therapeutics's EBITDA margin?

Aclaris Therapeutics (ACRS) reported EBITDA margin of -1,045% in Q2 2026.

How has Aclaris Therapeutics's EBITDA margin changed year-over-year?

Aclaris Therapeutics's EBITDA margin decreased by 20.1% year-over-year, from -870.1% to -1,045%.

What is the long-term trend for Aclaris Therapeutics's EBITDA margin?

Over 4 years (2021 to 2025), Aclaris Therapeutics's EBITDA margin has grown at a -7.3% compound annual growth rate (CAGR), from -1,313.4% to -970.1%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.